Corium International Inc

Corium International — Technical Presentation (July 2015)

15 slides from Corium International's technical presentation, Jul 28, 2015

  1. Slide 1: MicroCor hPTH(1-34) Phase 2a Interim Topline Results

    © 2015 Corium All Rights Reserved. Corium International, Inc. July 28, 2015 MicroCor hPTH(1-34) Phase 2a Interim Topline Results

  2. Slide 2: MicroCor Platform Overview

    MicroCor Platform Overview ~10 mm ~200 µm ~40 mm Applicator Array Cross-Section

  3. Slide 3: MicroCor Operation

    MicroCor Operation Dissolvable Drug-in-Tip Insoluble Backing Layer Controlled Application Stratum Corneum Dermis Blood vessels Epidermis ~200µm

  4. Slide 4: Phase 2a Study Overview

    Phase 2a Study Overview Part A Pharmacokinetics (PK) 18 Subjects 3 Days In-clinic 2 MicroCor Doses + Forteo Injection Part B PK + Pharmacodynamics (PD) 21 Subjects 28 Days Take-home 1 MicroCor Dose or Forteo Injection . Part A: PK only; FDA guidance to demonstrate PK in target age group - Crossover

  5. Slide 5: Phase 2a—Part A Design (PK Only)

    Phase 2a—Part A Design (PK Only) . Single-dose, randomized, crossover study .18 healthy post-menopausal women (50-85 years of age) . Per FDA guidance, two MicroCor doses to establish dose proportionality: – 16 mcg targeted to achieve Cmaxcomparable to Forteo – 38 mcg targeted to achieve AUC* compara

  6. Slide 6: Phase 2a—Part B Design (PK/PD)

    Phase 2a—Part B Design (PK/PD) . Multiple-dose, randomized, parallel groups .21 healthy post-menopausal women (50-85 years of age) . Two treatment groups: – 38 mcg MicroCor(n=15) – 20 mcg Forteosubcutaneous injection (n=6) . Each subject dosed once per day for 28 consecutive days . First 4 doses app

  7. Slide 7: Rapid and Pulsatile Pharmacokinetics

    0 50 100 150 200 0 1 2 3 4 hPTH(1-34) plasma concentration (pg/ml) Hours MicroCor 38 mcg Day 1 (n=15) MicroCor 38 mcg Day 28 (n=14) Forteo 20 mcg Day 1 (n=6) Forteo 20 mcg Day 28 (n=4) Rapid and Pulsatile Pharmacokinetics . Dose proportional: Supports dose selection for Phase 2B . No drug accumulati

  8. Slide 8: Phase 2a PK Profiles Similar to Phase 1

    . PK profiles similar for younger (18-35) and older (50-85) subjects . Phase 1 PK profile reviewed with FDA as basis for Phase 2 study design Phase 2a PK Profiles Similar to Phase 1 0 50 100 150 200 0 1 2 3 4 hPTH(1-34) plasma concentrations (pg/ml) Hours MicroCor Phase 1 (n=16) MicroCor Phase 2a (n

  9. Slide 9: Reliable and Reproducible Dosing

    0 100 200 300 400 AUC (pg*hr/mL) Reliable and Reproducible Dosing CV=49% CV=30% . AUC variability in MicroCor PTH comparable to Forteoinjections MicroCor 38µg Forteo 20µg CV=43% MicroCor 38µg Forteo 20µg CV=32% Part A Part B CV=41% Day 1 Day 28 MicroCor 38µg

  10. Slide 10: Increase In Bone Formation Biomarker

    Increase In Bone Formation Biomarker *P1NP – Procollagen Type 1 N-terminal propeptide 0 50 100 150 0 7 14 21 28 35 42 49 56 P1NP (% change from baseline) Days MicroCor 38 mcg (n=14) Forteo 20 mcg (n=4) Treatment stopped . Serum P1NP* levels indicative of bone formation activity . Increase in P1NP wi

  11. Slide 11: Little Change in Bone Resorption Biomarker

    -40 -20 0 20 40 60 0 7 14 21 28 35 42 49 56 CTX (% change from baseline) Days Forteo 20 mcg (n=4) MicroCor 38 mcg (n=14) Little Change in Bone Resorption Biomarker *CTX – collagen Type 1 cross-linked linked C-telopeptide . Higher serum levels of CTX* are indicative of bone loss . CTX levels with Mic

  12. Slide 12: Excellent Safety and Skin Tolerability

    Excellent Safety and Skin Tolerability .545 MicroCor applications in Phase 2a showed excellent skin tolerability –95% of applications resulted in minimal (score of 1/8) skin irritation (erythema only) – Highest reported score was 2/8 – E rythema was transient, limiting and self-resolving – No other

  13. Slide 13: Key Phase 2a Conclusions

    Key Phase 2a Conclusions .Excellent safety and skin tolerability .Rapid and reproducible PK in target age group (50-85) .Results confirmed PK profile seen in younger Phase 1 study age group (18-35) .Bone biomarkersconsistent with Forteo .Ease and reproducibility of self-administration validated Resu

  14. Slide 14: Planned Phase 2b Trial Design

    Planned Phase 2b Trial Design .Efficacy andsafety study in 150-200 post-menopausal osteoporotic women .Three MicroCor doses with Forteo 20 mcg as active comparator .Six-month study duration with daily self-administration of treatments .Trial could commence in late CY 2016 .Partnering or co-developme

  15. Slide 15: © 2015 Corium All Rights Reserved. Corium International, Inc. July 28, 2015

    © 2015 Corium All Rights Reserved. Corium International, Inc. July 28, 2015 Nasdaq: CORI

Corium International — Technical Presentation (July 2015) on 6ix